alexa Lupus nephritis | Brazil| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Relevant Topics

Lupus Nephritis

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Lupus nephritis

    Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys. To analyse the relationships between ethnicity and the prevalence and severity of lupus nephritis (LN) in patients attending a tertiary referral centre (The Royal Melbourne Hospital (RMH)).

  • Lupus nephritis

    The overall causes of death in lupus are much more varied than in other forms of primary glomerulonephritis, in which renal failure is the dominant cause. It must be remembered that the data in this table cover a considerable time span, and that they may not reflect contemporary events—particularly in relation to treatment-related deaths such as sepsis. Only 10 to 15% of patient with lupus nephritis now go into end-stage renal failure (15,17), and sepsis is the principal cause of actual death in lupus nephritis.

  • Lupus nephritis

    In the treatment of lupus nephritis, we are dealing with two quite distinct therapeutic problems: the induction treatment of severe acute life-threatening disease, often affecting many systems and usually near the onset of the disease; here, the threat of the disease is paramount; and (2) the maintenance treatment and long-term management of chronic, more or less indolent disease, during which protection from the side effects of treatment becomes more and more important

  • Lupus nephritis

    The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active, biopsy-proven Lupus Nephritis. The secondary objectives of this study are to assess the safety and tolerability of BIIB023 compared with placebo in this study population. Participants who complete this study through Week 52 will be offered the option to enter an Extension study under a separate protocol 211LE202 (NCT0193089).

Expert PPTs

Speaker PPTs


High Impact List of Articles

Conference Proceedings